A successful regulatory strategy can have a flywheel effect on a medtech start-up’s pathway. Our CEO Daniele Zanotti will explain how at the upcoming 6th Qserve MedTech Conference in Amsterdam.
On 12 November, Daniele will join two back-to-back sessions with Qserve Group, TÜV SÜD and BSI, sharing a start-up’s perspective on the regulatory journey to get a medical device from development to market.
Join him for more insights:
- Start-Up Survival Guide: Overcoming Regulatory Challenges – EU vs USA: Building a regulatory strategy that scales, and putting resources where they count
- Clinical Challenges for Start-Ups: From Evidence to Approval: Generating the right clinical evidence in the most time- and cost-effective way
At LSI Europe, Daniele argued that clinical validation should be a scalable ladder, not a high-jump competition. Amsterdam takes that conversation further: meaningful evidence can speed up a device’s path to real-life medicine and, as a result, a company’s ability to scale.
At StarTric, the regulatory pathway and the clinical programme are one plan, built to demonstrate TriClover’s efficacy on outcomes that matter to patients.
